{"nctId":"NCT00955552","briefTitle":"Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee","startDateStruct":{"date":"2010-08"},"conditions":["Osteoarthritis of the Knee"],"count":100,"armGroups":[{"label":"Cosamin DS®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cosamin DS® (Nutramax)"]},{"label":"Glucosamine/ chondroitin sulphate","type":"EXPERIMENTAL","interventionNames":["Drug: Glucosamine sulphate and chondroitin sulphate association"]}],"interventions":[{"name":"Glucosamine sulphate and chondroitin sulphate association","otherNames":["Glucosamine sulphate and Chondroitin sulphate"]},{"name":"Cosamin DS® (Nutramax)","otherNames":["Cosamin DS®","glucosamine hydrochloride and chondroitin sulphate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects have to read and sign the approved the Informed Consent form prior to any participation in the study.\n* Male or female Subjects, aged upper to 40 years.\n* Osteoarthritis of the knee confirmed by radiological examination.\n* Visual analogue scale (VAS) \\> 40 mm.\n* Kellgren and Lawrence grade 1 to 3.\n* Clinical diagnosis of pain and functional limitation.\n\nExclusion Criteria:\n\n* History of significant trauma or surgery in the affected joint.\n* Pregnant women, lactating or not using appropriate contraceptive method.\n* History or presence of active rheumatic disease that may be responsible for secondary osteoarthritis.\n* Severe inflammation of the joint confirmed by physical examination (excluding also erythrocyte sedimentation \\<40mm/h and rheumatoid factor \\<1:40).\n* Body mass index \\> 30.\n* Hematologic abnormalities, liver, renal or metabolic functions which undermine the serious participation of the patient (at investigator's criteria).\n* Systemic administration and/or intra-articular corticosteroids in the last 3 months.\n* Have made use of glucosamine and/or chondroitin.\n* Lequesne index of \\> 12.\n* Arthroplasty in the affected joint.\n* Use of narcotic analgesics.\n* Any condition that, in the opinion of the investigator, renders the patient unable to participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Assess the Efficacy and Safety of the Association of Glucosamine Sulphate 500 mg/Chondroitin Sulphate 400 mg (Eurofarma) in the Treatment of Osteoarthritis, Compared to Cosamin DS® (Nutramax)in Same Presentation and Pharmaceutical Form","description":"To assess the efficacy and safety of the association of glucosamine sulphate 500 mg/chondroitin sulphate 400 mg (Eurofarma) in the treatment of osteoarthritis, compared to Cosamin DS® (Nutramax) in same presentation and pharmaceutical form.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"88.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Hyperglycemia","Worsening Diabetes Mellitus","Nausea","headache","Leg pain"]}}}